Richard A. Larson to Neoplasm, Residual
This is a "connection" page, showing publications Richard A. Larson has written about Neoplasm, Residual.
Connection Strength
0.512
-
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 02 18; 11(2):39.
Score: 0.171
-
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010 Oct 10; 28(29):4500-6.
Score: 0.083
-
The U.S. trials in adult acute lymphoblastic leukemia. Ann Hematol. 2004; 83 Suppl 1:S127-8.
Score: 0.052
-
Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol. 2003 Jul; 10(4):284-9.
Score: 0.050
-
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 09 22; 140(12):1345-1377.
Score: 0.048
-
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001 Jun 01; 97(11):3574-80.
Score: 0.044
-
Treatment of adult acute lymphoblastic leukemia. Semin Oncol. 1997 Feb; 24(1):70-82.
Score: 0.032
-
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 01 26; 129(4):424-447.
Score: 0.032